+38 068 889 89 89
00380689869898 (汉语)
00380930552240 (لغه العربية)
00380930552240 (باللغة العربية)
+38 044 223 28 95
Contact us


Fetal stem cell treatment is not an alternative to standard protocols of treating cancer. Stem cell therapy is possible only after surgery and/or traditional chemo- and/or radiotherapy, in case they are indicated to the patient.

We accept for treatment patients with stabilized condition proved by results of instrumental and laboratory findings there should be no primary tumor growth or new metastasis formation.

As conventional cancer treatment has many side effects, stem cell treatment is aimed mainly at:

  • Partial restoration of anti-tumor immunity and haemopoesis;
  • Improvement in patient’s quality of life – reduced weakness, better overall condition, both physical and psycho-emotional.

During the first month after stem cell treatment, our patients may observe the following effects:

  • improved overall condition and appetite;
  • diminished weakness and sweating;
  • increased capacity to work and self-care ability;
  • better emotional status, cognitive abilities and memory.

Within one to two months after fetal stem cells treatment, other positive effects develop (some of them translate into improved laboratory findings), in particular:

  • improved haemopoesis;
  • improved immunological profile;
  • reduced levels of inflammatory markers;
  • higher quality of life.

Fetal stem cell therapy contributes to formation of anti-tumor immunity, which is crucial for preventing relapse and metastatic process. However, stem cell treatment is possible only after traditional treatment.

Our methods have been approved by the Ministry of Health of Ukraine on April 20, 1999 and have been recommended for use in clinical practice.

Application of Fetal Stem Cell Suspensions in Complex Treatment of Cancer Patients (poster presentation).
Ukrainian, jpg, 2.6 Mb


Patient U.M., 57 C-r glandullae bilateralis; condition after combined therapy; prolongatio morbi 

Medical case reports

Left-side Wilms tumour, grade III, class II
Acute lymphoblastic leukemia
Breast cancer
Ovarian cancer grade IV, clinical group II

Request additional information

Our stories

Our patents